Unlocking Opportunities: Securing Time for a New Clinical Trial
In late 2011, Richard Valdes experienced a minor discomfort just above his stomach that would lead him on a challenging journey through pancreatic cancer. Initially dismissed as a minor issue, it wasn’t until a physical exam in February 2012 that doctors began to investigate further. After a year of tests, a CT scan in January 2013 revealed a mass on the tail of his pancreas, marking the beginning of a battle against a disease that claimed many lives. Thankfully, Richard’s cancer was isolated, allowing for surgical intervention.
Surgical Intervention and Initial Treatments
Richard’s wife, an operating room nurse, recognized the urgency of their situation and referred him to Dr. Brendan Visser at Stanford, a renowned expert in pancreatic surgery. In a successful operation, 40% of Richard’s pancreas was removed. Following his recovery, he underwent a rigorous treatment plan, which included chemotherapy, radiation, and participation in a phase III immunotherapy trial focused on a pancreatic vaccine developed by New Link. By September 2013, Richard was declared cancer-free, but the reprieve was short-lived.
Setbacks and New Trials
By March 2014, Richard’s health took a turn for the worse when the cancer metastasized, spreading to his lungs and liver. Diagnosed with stage IV pancreatic cancer, Richard faced a grim prognosis of just one year. He was put on a challenging chemotherapy regimen known as FOLFIRINOX, a combination of powerful medications designed to combat aggressive cancers. During this period, Richard documented his journey on Facebook, which not only served as therapy for him but also garnered support from friends and family.
Exploring New Treatment Options
After enduring a year of FOLFIRINOX, Richard’s oncologist, Dr. Pamela Kunz, suggested a temporary break from chemotherapy to recover from its debilitating side effects. During this hiatus, the cancer returned, prompting Richard to enroll in a phase II clinical trial utilizing a monoclonal antibody and a different pancreatic vaccine, GVAX. He once again collaborated with Dr. Fisher, emphasizing that clinical trials are crucial in the ongoing fight against cancer.
Resuming Chemotherapy with Positive Results
Unfortunately, the new trial did not yield the hoped-for results, and the cancer spread further. Facing a dire situation, Richard began a third chemotherapy regimen featuring Gemzar and Abraxane. In a turn of good fortune, subsequent scans indicated that this treatment was effective, causing significant tumor reduction, some by nearly 50%. Richard remained optimistic, believing that a smaller tumor burden would improve his chances in future clinical trials.
The Importance of Support and Positivity
Richard understood that the road ahead would be filled with challenges, but he was not alone. His unwavering support system, including his wife and daughter, played a vital role in maintaining his morale. They faced the ups and downs of his treatment together, cultivating a positive outlook as they looked forward to many more years of life.
Sadly, Richard Valdes passed away on July 29, 2019, after a valiant struggle with pancreatic cancer. His relentless pursuit of new treatments and advocacy for increased funding for pancreatic cancer research exemplified a "never give up" spirit. Our deepest condolences go out to his family and all who had the privilege of knowing him.
Seeking Clinical Trials
For those navigating similar challenges, understanding how to locate clinical trials can be invaluable. Learn more about finding clinical trials here.
